Si Ni Powder enhances doxorubicin efficacy in sleep-deprived breast cancer by modulating the tumor microenvironment
In an orthotopic 4T1 breast cancer mouse model, sleep deprivation weakened the antitumor effect of doxorubicin, which was effectively rescued by Si Ni Powder. SNP counteracted SD-induced inflammatory signaling, extracellular matrix remodeling, and lipid metabolic pathways, with 168 chemical components identified and 20 detected in tumor tissues.
Evidence Score
Study Evidence
Study 1. Si Ni Powder enhances chemotherapy efficacy in sleep-deprived breast cancer via modulation of the tumor microenvironment.
observationalJia H, Chen Y, Cheng H, Yao S, Wang Q, Qian M, Ge C, Huang Z, Chen Y ยท Translational cancer research (2026)
Result:
Mechanism Graph
Limitations
- โ Animal model only; results may not directly translate to humans
- โ Specific dose and administration regimen of SNP not reported in abstract
Frequently Asked Questions
What is Si Ni Powder?โผ
Si Ni Powder is a traditional Chinese medicine formulation known for sleep-improving properties, tested here for its ability to enhance chemotherapy in sleep-deprived breast cancer.
How does sleep deprivation affect chemotherapy?โผ
Sleep deprivation weakens the antitumor effect of doxorubicin by activating inflammatory signaling, extracellular matrix remodeling, and lipid metabolic pathways in the tumor microenvironment.
What are the key molecular targets of SNP?โผ
Integrated analyses identified six key targets: Stat3, Stat6, Ppara, Rxra, Ar, and Hes1, with strong interactions from compounds like neoeriocitrin and genistein.
Is this study in humans or animals?โผ
This study used an orthotopic 4T1 breast cancer mouse model, so it is preclinical animal research.
Products
Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.
References
- 1.Jia H, Chen Y, Cheng H, Yao S, Wang Q, Qian M, Ge C, Huang Z, Chen Y. "Si Ni Powder enhances chemotherapy efficacy in sleep-deprived breast cancer via modulation of the tumor microenvironment.." Translational cancer research, 2026. PMID: 42445414 DOI: 10.21037/tcr-2026-0517